Famularo S, Donadon M, Cipriani F, et al. - In this multicentric Italian study, researchers sought to compare the Survival after Recurrence of curative (surgery or thermoablation) vs palliative (TACE or Sorafenib) treatments for patients with recurrent hepatocellular carcinoma. Data were collected between 2007 and 2018 from 16 centers. Listed patients were then divided into Curative (CUR) or Palliative (PAL) Group according to treatment allocation. One thousand five hundred sixty patients were assessed, of which 421 experienced recurrence and were then eligible: 156 in CUR group and 256 in PAL group. The only predictors of mortality after recurrence were palliative care and having a median recurrent nodule size > 5 cm, while the only protective factor was time to recurrence. In case of recurrence, curative approaches may guarantee long-term survival.